MCID: CNT018
MIFTS: 37

Central Nervous System Leukemia

Categories: Blood diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Leukemia

MalaCards integrated aliases for Central Nervous System Leukemia:

Name: Central Nervous System Leukemia 12 15 73
Leukemia of the Cns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12969
NCIt 50 C5440
UMLS 73 C1332884

Summaries for Central Nervous System Leukemia

Disease Ontology : 12 A hematologic cancer located in the central nervous system.

MalaCards based summary : Central Nervous System Leukemia, also known as leukemia of the cns, is related to lymphocytic leukemia and acute lymphocytic leukemia. An important gene associated with Central Nervous System Leukemia is AFDN (Afadin, Adherens Junction Formation Factor), and among its related pathways/superpathways are Tight junction and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Vincristine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and myeloid, and related phenotype is Synthetic lethal with vaccinia virus (VACV) infection.

Related Diseases for Central Nervous System Leukemia

Graphical network of the top 20 diseases related to Central Nervous System Leukemia:



Diseases related to Central Nervous System Leukemia

Symptoms & Phenotypes for Central Nervous System Leukemia

GenomeRNAi Phenotypes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.8 AFDN MME RUNX1

Drugs & Therapeutics for Central Nervous System Leukemia

Drugs for Central Nervous System Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
2
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
3
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
4
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
6
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
9
Daunorubicin Approved Phase 3 20830-81-3 30323
10
Thioguanine Approved Phase 3 154-42-7 2723601
11
Hydrocortisone Approved, Vet_approved Phase 3,Phase 1 50-23-7 5754
12
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1 130167-69-0
13
Dasatinib Approved, Investigational Phase 3 302962-49-8 3062316
14
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
15
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
16
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
17
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 1 50-03-3
18
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
19
Cortisone acetate Approved, Investigational Phase 3 1950-04-4, 50-04-4 5745
20
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
22
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
23
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1 22916-47-8 4189
26
Busulfan Approved, Investigational Phase 3 55-98-1 2478
27
Mesna Approved, Investigational Phase 3 3375-50-6 598
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
29
Doxil Approved June 1999 Phase 3,Phase 2 31703
30
Cortisone Experimental Phase 3 53-06-5 222786
31
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
32 Immunologic Factors Phase 3,Phase 2,Phase 1
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
35 Vitamin B9 Phase 3,Phase 2
36 Protein Kinase Inhibitors Phase 3,Phase 2
37 Antimetabolites, Antineoplastic Phase 3,Phase 2
38 Antimitotic Agents Phase 3,Phase 2
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
40 Antimetabolites Phase 3,Phase 2
41 Vitamin B Complex Phase 3,Phase 2
42 Folic Acid Antagonists Phase 3,Phase 2
43 Folate Phase 3,Phase 2
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
45 6-Mercaptopurine Phase 3,Phase 2
46 Dermatologic Agents Phase 3,Phase 2
47 Hormone Antagonists Phase 3,Phase 2
48
asparaginase Phase 3,Phase 1
49 Etoposide phosphate Phase 3,Phase 2
50 Antidotes Phase 3

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
2 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL Recruiting NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
3 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
4 Treatment of Acute Lymphoblastic Leukemia in Children Active, not recruiting NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
5 Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia Terminated NCT00002961 Phase 3 cyclophosphamide;cyclosporine;etoposide;methotrexate;Busulfan;Mesna
6 Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. Unknown status NCT00149136 Phase 2 imatinib
7 Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System Terminated NCT01596127 Phase 1, Phase 2 Intrathecal Rituximab
8 CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia Recruiting NCT03064269 Phase 1
9 Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) Withdrawn NCT00957320 Phase 1 Sirolimus;PEG-asparaginase
10 Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy Unknown status NCT01661413
11 Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer Unknown status NCT01295463

Search NIH Clinical Center for Central Nervous System Leukemia

Genetic Tests for Central Nervous System Leukemia

Anatomical Context for Central Nervous System Leukemia

MalaCards organs/tissues related to Central Nervous System Leukemia:

41
Bone, T Cells, Myeloid, Brain, B Cells, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Leukemia:

19
The Central Nervous System

Publications for Central Nervous System Leukemia

Articles related to Central Nervous System Leukemia:

(show top 50) (show all 73)
# Title Authors Year
1
Experiment research of focused ultrasound combined with drug and microbubble for treatment of central nervous system leukemia. ( 29435190 )
2018
2
Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. ( 30102203 )
2018
3
Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report. ( 30407314 )
2018
4
Chronic myeloid leukemia extramedullary blast crisis presenting as central nervous system leukemia: A case report. ( 30407337 )
2018
5
Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor. ( 30518632 )
2018
6
Central nervous system leukemia in a patient with concurrent nasopharyngeal carcinoma and acute myeloid leukaemia: A case report. ( 29384905 )
2017
7
Establishment of NOD/SCID mouse model of central nervous system leukemia. ( 24927394 )
2014
8
Comprehensive craniospinal radiation for controlling central nervous system leukemia. ( 25539370 )
2014
9
Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia? ( 21398042 )
2011
10
Predictive role of cerebrospinal fluid hydrogen sulfide in central nervous system leukemia. ( 22340157 )
2011
11
Controversies in the management of central nervous system leukemia. ( 20469977 )
2010
12
[Central nervous system leukemia mimicking rapidly progressive HTLV-1 associated myelopathy]. ( 19491526 )
2009
13
Primary central nervous system leukemia presenting with an isolated oculomotor palsy. ( 18710807 )
2008
14
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. ( 18661773 )
2008
15
Central nervous system leukemia on magnetic resonance imaging. ( 18310989 )
2008
16
Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. ( 17487757 )
2007
17
Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. ( 17924103 )
2007
18
Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction. ( 15681484 )
2005
19
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. ( 14581336 )
2003
20
Bilateral optic nerve infiltration in central nervous system leukemia. ( 12504706 )
2003
21
Central nervous system leukemia recurring over more than 16 years. ( 10797368 )
2000
22
Primary central nervous system leukemia with a novel chromosomal translocation. ( 9335020 )
1997
23
Central nervous system leukemia. ( 8868094 )
1996
24
Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. ( 7537120 )
1995
25
The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. ( 8319175 )
1993
26
Cerebrospinal fluid neopterin levels in children with central nervous system leukemia. ( 8348070 )
1993
27
Temporal bone findings in central nervous system leukemia. ( 1812774 )
1991
28
Tumor necrosis factor in the cerebrospinal fluid of children with central nervous system leukemia. ( 1901928 )
1991
29
Effective prevention of central nervous system leukemia with intrathecal methotrexate and intrathecal methotrexate, cytosine arabinoside, and hydrocortisone in childhood acute lymphocytic leukemia. ( 2323651 )
1990
30
Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine. ( 2766280 )
1989
31
Central nervous system leukemia. ( 3047654 )
1988
32
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. ( 3052630 )
1988
33
Elevation of cerebrospinal fluid sialic acid concentration in children with central nervous system leukemia. ( 3296627 )
1987
34
Significance of cerebrospinal fluid ferritin estimation in central nervous system leukemia. ( 3113843 )
1987
35
Intermittent central nervous system irradiation and intrathecal chemotherapy for central nervous system leukemia in children. ( 3624023 )
1987
36
Pickwickian syndrome related to central nervous system leukemia. ( 3458358 )
1986
37
Millipore filter vs cytocentrifuge for detection of childhood central nervous system leukemia. ( 2425776 )
1986
38
The central nervous system leukemia: a clinical and pathological study. ( 3860195 )
1985
39
A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). ( 3857943 )
1985
40
Central nervous system leukemia in children with acute nonlymphoblastic leukemia. ( 3840394 )
1985
41
Intrathecal methotrexate versus central nervous system leukemia. ( 6399986 )
1984
42
Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. ( 6366149 )
1984
43
Recognition of central nervous system leukemia by flow cytometry. ( 6596184 )
1984
44
Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. ( 6366138 )
1983
45
Diabetes insipidus associated with central nervous system leukemia. ( 7123345 )
1982
46
Aziridinylbenzoquinone (AZQ) treatment of central nervous system leukemia. ( 6958367 )
1982
47
Central nervous system leukemia and lymphoma: computed tomographic manifestations. ( 6976091 )
1981
48
Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. ( 288969 )
1979
49
Scanning electron microscopic study on central nervous system leukemia in children. ( 292293 )
1979
50
Central nervous system leukemia. ( 267618 )
1977

Variations for Central Nervous System Leukemia

Expression for Central Nervous System Leukemia

Search GEO for disease gene expression data for Central Nervous System Leukemia.

Pathways for Central Nervous System Leukemia

Pathways related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.6 AFDN RUNX1
2 11.39 CD19 MME
3 11.13 CD19 MME
4 11.02 CR1 MME
5 10.79 CD19 CR1 MME
6 10.68 CD19 MME

GO Terms for Central Nervous System Leukemia

Cellular components related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule membrane GO:0030667 8.62 CR1 MME

Biological processes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of complement activation GO:0030449 9.16 CD19 CR1
2 neutrophil degranulation GO:0043312 9.13 CDA CR1 MME
3 regulation of regulatory T cell differentiation GO:0045589 8.62 CR1 RUNX1

Sources for Central Nervous System Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....